Search

Your search keyword '"Metz, Martin"' showing total 255 results
Start Over Author "Metz, Martin" Search Limiters Full Text
255 results on '"Metz, Martin"'

4. Fenebrutinib in H.sub.1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial

Author

Metz, Martin, Sussman, Gordon, Gagnon, Rémi, Staubach, Petra, Tanus, Tonny, Yang, William H., and Lim, Jeremy J.

Subjects
Autoimmunity -- Analysis, Urticaria -- Diagnosis -- Care and treatment -- Risk factors, Antihistamines -- Testing, BCR-ABL tyrosine kinase inhibitors -- Testing, Biological sciences, Health
Abstract

Bruton's tyrosine kinase (BTK) is crucial for Fc[epsilon]RI-mediated mast cell activation and essential for autoantibody production by B cells in chronic spontaneous urticaria (CSU). Fenebrutinib, an orally administered, potent, highly selective, reversible BTK inhibitor, may be effective in CSU. This double-blind, placebo-controlled, phase 2 trial (EudraCT ID 2016-004624-35) randomized 93 adults with antihistamine-refractory CSU to 50 mg daily, 150 mg daily and 200 mg twice daily of fenebrutinib or placebo for 8 weeks. The primary end point was change from baseline in urticaria activity score over 7 d (UAS7) at week 8. Secondary end points were the change from baseline in UAS7 at week 4 and the proportion of patients well-controlled (UAS7 [less than or equal to] 6) at week 8. Fenebrutinib efficacy in patients with type IIb autoimmunity and effects on IgG-anti-Fc[epsilon]RI were exploratory end points. Safety was also evaluated. The primary end point was met, with dose-dependent improvements in UAS7 at week 8 occurring at 200 mg twice daily and 150 mg daily, but not at 50 mg daily of fenebrutinib versus placebo. Asymptomatic, reversible grade 2 and 3 liver transaminase elevations occurred in the fenebrutinib 150 mg daily and 200 mg twice daily groups (2 patients each). Fenebrutinib diminished disease activity in patients with antihistamine-refractory CSU, including more patients with refractory type IIb autoimmunity. These results support the potential use of BTK inhibition in antihistamine-refractory CSU. Fenebrutinib, an oral Bruton's tyrosine kinase inhibitor, reduces disease activity in patients with chronic spontaneous urticaria refractory to antihistamines, suggesting that this treatment type could be an alternative to standard of care anti-IgE therapy., Author(s): Martin Metz [sup.1] [sup.2] , Gordon Sussman [sup.3] , Rémi Gagnon [sup.4] , Petra Staubach [sup.5] , Tonny Tanus [sup.6] , William H. Yang [sup.7] , Jeremy J. Lim [...]

Published
2021
Full Text
View/download PDF

5. CRUSE®-An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

Author

Neisinger, Sophia, Sousa Pinto, Bernardo, Ramanauskaite, Aiste, Bousquet, Jean, Weller, Karsten, Metz, Martin, Magerl, Markus, Kocatuerk, Emek, Cherrez-Ojeda, Ivan, Gimenez-Arnau, Ana M., Parisi, Claudio Alberto S., Altrichter, Sabine, Ensina, Luis Felipe, Bouillet, Laurence, Asero, Riccardo, Goncalo, Margarida, Guillet, Carole, Rutkowski, Krzysztof, Bernstein, Jonathan A., Hardin, Hannah, Godse, Kiran, Brzoza, Zenon, Sousa, Jose Ignacio Larco, Thomsen, Simon Francis, van Doorn, Martijn, Hide, Michihiro, Ye, Young-Min, Vanderse, Staffan, Lapina, Lasma, Peter, Jonny, Zhao, Zuotao, Han, Lianyi, Nasr, Iman, Rockmann-Helmbach, Heike, Sorensen, Jennifer Astrup, Kara, Rabia oeztas, Kurjane, Natalja, Kurchenko, Andrii I., Kaidashev, Igor, Tsaryk, Vladyslav, Stepanenko, Roman, Maurer, Marcus, Neisinger, Sophia, Sousa Pinto, Bernardo, Ramanauskaite, Aiste, Bousquet, Jean, Weller, Karsten, Metz, Martin, Magerl, Markus, Kocatuerk, Emek, Cherrez-Ojeda, Ivan, Gimenez-Arnau, Ana M., Parisi, Claudio Alberto S., Altrichter, Sabine, Ensina, Luis Felipe, Bouillet, Laurence, Asero, Riccardo, Goncalo, Margarida, Guillet, Carole, Rutkowski, Krzysztof, Bernstein, Jonathan A., Hardin, Hannah, Godse, Kiran, Brzoza, Zenon, Sousa, Jose Ignacio Larco, Thomsen, Simon Francis, van Doorn, Martijn, Hide, Michihiro, Ye, Young-Min, Vanderse, Staffan, Lapina, Lasma, Peter, Jonny, Zhao, Zuotao, Han, Lianyi, Nasr, Iman, Rockmann-Helmbach, Heike, Sorensen, Jennifer Astrup, Kara, Rabia oeztas, Kurjane, Natalja, Kurchenko, Andrii I., Kaidashev, Igor, Tsaryk, Vladyslav, Stepanenko, Roman, and Maurer, Marcus

Abstract

Background: Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE ®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need. Methods: CRUSE ® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE ® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE ® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations. Results: CRUSE ® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days. Conclusions: The initial data from CRUSE ® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.

Published
2024

7. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

Author

Neisinger, Sophia, primary, Sousa Pinto, Bernardo, additional, Ramanauskaite, Aiste, additional, Bousquet, Jean, additional, Weller, Karsten, additional, Metz, Martin, additional, Magerl, Markus, additional, Kocatürk, Emek, additional, Cherrez‐Ojeda, Ivan, additional, Gimenez‐Arnau, Ana M., additional, Parisi, Claudio Alberto S., additional, Altrichter, Sabine, additional, Ensina, Luis Felipe, additional, Bouillet, Laurence, additional, Asero, Riccardo, additional, Gonçalo, Margarida, additional, Guillet, Carole, additional, Rutkowski, Krzysztof, additional, Bernstein, Jonathan A., additional, Hardin, Hannah, additional, Godse, Kiran, additional, Brzoza, Zenon, additional, Sousa, Jose Ignacio Larco, additional, Thomsen, Simon Francis, additional, van Doorn, Martijn, additional, Hide, Michihiro, additional, Ye, Young‐Min, additional, Vanderse, Staffan, additional, Lapiņa, Lāsma, additional, Peter, Jonny, additional, Zhao, Zuotao, additional, Han, Lianyi, additional, Nasr, Iman, additional, Rockmann‐Helmbach, Heike, additional, Sørensen, Jennifer Astrup, additional, Kara, Rabia Öztaş, additional, Kurjāne, Natalja, additional, Kurchenko, Andrii I., additional, Kaidashev, Igor, additional, Tsaryk, Vladyslav, additional, Stepanenko, Roman, additional, and Maurer, Marcus, additional

Published
2024
Full Text
View/download PDF

8. In the skin lesions of patients with mycosis fungoides, the number of MRGPRX2-expressing cells is increased and correlates with mast cell numbers

Author

Hu, Man, primary, Pyatilova, Polina, additional, Altrichter, Sabine, additional, Sheng, Caibin, additional, Liu, Nian, additional, Terhorst-Molawi, Dorothea, additional, Lohse, Katharina, additional, Ginter, Katharina, additional, Puhl, Viktoria, additional, Maurer, Marcus, additional, Metz, Martin, additional, and Kolkhir, Pavel, additional

Published
2023
Full Text
View/download PDF

9. Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey

Author

Krause, Karoline, primary, Bonnekoh, Hanna, additional, Jelden‐Thurm, Jannis, additional, Asero, Riccardo, additional, Gimenez‐Arnau, Ana Maria, additional, Cardoso, José C., additional, Grattan, Clive, additional, Kocatürk, Emek, additional, Lippert, Undine, additional, Maurer, Marcus, additional, Metz, Martin, additional, Staubach, Petra, additional, Goncalo, Margarida, additional, and Kolkhir, Pavel, additional

Published
2023
Full Text
View/download PDF

11. In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria

Author

Moñino‐Romero, Sherezade, primary, Kolkhir, Pavel, additional, Szépfalusi, Zsolt, additional, Schoepke, Nicole, additional, Metz, Martin, additional, Asero, Riccardo, additional, Ferrer, Marta, additional, Gimenez‐Arnau, Ana, additional, Grattan, Clive E. H., additional, Jakob, Thilo, additional, Konstantinou, George N., additional, Raap, Ulrike, additional, Staubach, Petra, additional, Zhang, Ke, additional, Bindslev‐Jensen, Carsten, additional, Daschner, Alvaro, additional, Kinaciyan, Tamar, additional, Makris, Michael, additional, Marrouche, Nadine, additional, Schmid‐Grendelmeier, Peter, additional, Sussman, Gordon, additional, Toubi, Elias, additional, Maurer, Marcus, additional, and Altrichter, Sabine, additional

Published
2023
Full Text
View/download PDF

13. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria.

Author

Neisinger, Sophia, Sousa Pinto, Bernardo, Ramanauskaite, Aiste, Bousquet, Jean, Weller, Karsten, Metz, Martin, Magerl, Markus, Kocatürk, Emek, Cherrez‐Ojeda, Ivan, Gimenez‐Arnau, Ana M., Parisi, Claudio Alberto S., Altrichter, Sabine, Ensina, Luis Felipe, Bouillet, Laurence, Asero, Riccardo, Gonçalo, Margarida, Guillet, Carole, Rutkowski, Krzysztof, Bernstein, Jonathan A., and Hardin, Hannah

Subjects
PATIENT monitoring, URTICARIA, PATIENT reported outcome measures, SELF-evaluation, SYMPTOMS
Abstract

Background: Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user‐friendly platform to complete patient‐reported outcome measures (PROMs) on their mobile devices. CRUSE®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need. Methods: CRUSE® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real‐time insights. Additionally, CRUSE® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations. Results: CRUSE® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country‐specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second‐generation antihistamines were used in 74.0% of days. Conclusions: The initial data from CRUSE® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. IFSI-guideline on chronic prurigo including prurigo nodularis

Author

Ständer, Sonja, Pereira, Manuel P., Berger, Timothy, Zeidler, Claudia, Augustin, Matthias, Bobko, Svetlana, Brenaut, Emilie, Chen, Suephy C., Chisolm, Sarah, Dalgard, Florence J., Elberling, Jesper, Elmariah, Sarina B., Evers, Andrea W.M., Garcovich, Simone, Gonçalo, Margarida, Halvorsen, Jon A., Kim, Brian S., Kupfer, Jörg, Kwatra, Shawn G., Lambert, Julien, Legat, Franz J., Lerner, Ethan A., Leslie, Tabi A., Lönndahl, Louise, Lvov, Andrey, Metz, Martin, Misery, Laurent, Papadavid, Evangelia, Potekaev, Nikolay N., Reich, Adam, Savk, Ekin, Schneider, Gudrun, Schut, Christina, Serra-Baldrich, Esther, Ständer, Hartmut F., Streit, Markus, Szepietowski, Jacek C., Tharp, Michael D., Wallengren, Joanna, Nast, Alexander, Weisshaar, Elke, and Yosipovitch, Gil

Published
2020
Full Text
View/download PDF

15. CRUSE – What the first 100 days have taught us

Author

Neisinger, Sophia, primary, Pinto, Bernardo Sousa, additional, Ramanauskaite, Aiste, additional, Bousquet, Jean, additional, Weller, Karsten, additional, Metz, Martin, additional, Magerl, Markus, additional, Kocatürk, Emek, additional, Ojeda, Ivan Cherrez, additional, Gimenez-Arnau, Ana M, additional, and Maurer, Marcus, additional

Published
2023
Full Text
View/download PDF

16. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria

Author

Terhorst-Molawi, Dorothea, Hawro, Tomasz, Grekowitz, Eva Maria, Kiefer, Lea Alice, Merchant, Kunal, Alvarado, Diego, Thomas, Lawrence J., Hawthorne, Thomas R., Crowley, Elizabeth, Heath-Chiozzi, Margo E., Metz, Martin, Maurer, Marcus, and Publica

Subjects
chronic inducible urticaria, CDX-0159, symptomatic dermographism, barzolvolimab, cold urticaria
Abstract

Background: Chronic inducible urticaria (CIndU) is characterized by mast cell (MC)-mediated wheals in response to triggers: cold in cold urticaria (ColdU) and friction in symptomatic dermographism (SD). KIT receptor activation by stem cell factor (SCF) is essential for MC function. Barzolvolimab (CDX-0159) is a humanized antibody that inhibits KIT activation by SCF and was well tolerated in healthy volunteers with dose-dependent plasma tryptase suppression indicative of systemic mast cell ablation. Methods: This is an open-label, trial in patients with antihistamine refractory ColdU or SD, receiving one IV dose of barzolvolimab (3 mg/kg), with a 12-week follow-up. Primary endpoint was safety/tolerability; pharmacodynamic (PD)/clinical endpoints included serum tryptase, plasma SCF, skin MC histology, provocation tests, urticaria control test (UCT), and dermatology life quality index (DLQI). Results: Analysis populations were safety (n = 21) and pharmacodynamics/clinical activity (n = 20). Barzolvolimab was well tolerated; most adverse events were mild and resolved. Treatment resulted in significant depletion of skin MCs, decreased tryptase (

Published
2023

21. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases

Author

Ujiie, Hideyuki, primary, Rosmarin, David, additional, Schön, Michael P., additional, Ständer, Sonja, additional, Boch, Katharina, additional, Metz, Martin, additional, Maurer, Marcus, additional, Thaci, Diamant, additional, Schmidt, Enno, additional, Cole, Connor, additional, Amber, Kyle T., additional, Didona, Dario, additional, Hertl, Michael, additional, Recke, Andreas, additional, Graßhoff, Hanna, additional, Hackel, Alexander, additional, Schumann, Anja, additional, Riemekasten, Gabriela, additional, Bieber, Katja, additional, Sprow, Gant, additional, Dan, Joshua, additional, Zillikens, Detlef, additional, Sezin, Tanya, additional, Christiano, Angela M., additional, Wolk, Kerstin, additional, Sabat, Robert, additional, Kridin, Khalaf, additional, Werth, Victoria P., additional, and Ludwig, Ralf J., additional

Published
2022
Full Text
View/download PDF

22. Definition, aims, and implementation of GA(2) LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus; Werner, Aberer; Agondi, Rosana; Al-Ahmad, Mona; Al-Nesf, Maryam Ali; Ansotegui, Ignacio; Arnaout, Rand; Arruda, Luisa Karla; Asero, Riccardo; Aygoeren-Puersue, Emel; Banerji, Aleena; Bauer, Andrea; Ben-Shoshan, Moshe; Berardi, Alejandro; Bernstein, Jonathan A; Betschel, Stephen; Bindslev-Jensen, Carsten; Bizjak, Mojca; Boccon-Gibod, Isabelle; Bork, Konrad; Bouillet, Laurence; Boysen, Henrik Balle; Brodszki, Nicholas; Broesby-Olsen, Sigurd; Busse, Paula; Buttgereit, Thomas; Bygum, Anette; Caballero, Teresa; Campos, Regis A.; Cancian, Mauro; Cherrez-Ojeda, Ivan; Cohn, Danny M.; Costa, Celia; Craig, Timothy; Criado, Paulo Ricardo; Criado, Roberta F.; Csuka, Dorottya; Dissemond, Joachim; Du-Thanh, Aurelie; Ensina, Luis Felipe; Ertaş, Ragıp; Fabiani, Jose E.; Fantini, Claudio; Farkas, Henriette; Ferrucci, Silvia Mariel; Figueras-Nart, Ignasi; Fili, Natalia L.; Fomina, Daria; Fukunaga, Atsushi; Gelincik, Aslı; Gimenez-Arnau, Ana; Godse, Kiran; Gompels, Mark; Goncalo, Margarida; Gotua, Maia; Gower, Richard; Godse, Kiran; Gompels, Mark; Goncalo, Margarida; Gotua, Maia; Gower, Richard; Grumach, Anete S; Guidos-Fogelbach, Guillermo; Hide, Michihiro; Ilina, Natalia; Inomata, Naoko; Jakob, Thilo; Josviack, Dario O.; Kang, Hye-Ryun; Kaplan, Allen; Kasperska-Zajac, Alicja; Katelaris, Constance; Kessel, Aharon; Kleinheinz, Andreas; Kosnik, Mitja; Krasowska, Dorota; Kulthanan, Kanokvalai; Kumaran, M. Sendhil; Larco Sousa, Jose Ignacio; Longhurst, Hilary J.; Lumry, William; MacGinnitie, Andrew; Magerl, Markus; Makris, Michael P.; Malbran, Alejandro; Marsland, Alexander; Martinez-Saguer, Inmaculada; Medina, Iris V.; Meshkova, Raisa; Metz, Martin; Nasr, Iman; Nicolay, Jan; Nishigori, Chikako V.; Meshkova, Raisa; Metz, Martin; Nasr, Iman; Nicolay, Jan; Nishigori, Chikako; Ohsawa, Isao; Özyurt, Kemal; Papadopoulos, Nikolaos G.; Parisi, Claudio A. S.; Peter, Jonathan Grant; Pfuetzner, Wolfgang; Popov, Todor; Prior, Nieves; Ramon, German D.; Reich, Adam; Reshef, Avner; Rie, School of Medicine, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus; Werner, Aberer; Agondi, Rosana; Al-Ahmad, Mona; Al-Nesf, Maryam Ali; Ansotegui, Ignacio; Arnaout, Rand; Arruda, Luisa Karla; Asero, Riccardo; Aygoeren-Puersue, Emel; Banerji, Aleena; Bauer, Andrea; Ben-Shoshan, Moshe; Berardi, Alejandro; Bernstein, Jonathan A; Betschel, Stephen; Bindslev-Jensen, Carsten; Bizjak, Mojca; Boccon-Gibod, Isabelle; Bork, Konrad; Bouillet, Laurence; Boysen, Henrik Balle; Brodszki, Nicholas; Broesby-Olsen, Sigurd; Busse, Paula; Buttgereit, Thomas; Bygum, Anette; Caballero, Teresa; Campos, Regis A.; Cancian, Mauro; Cherrez-Ojeda, Ivan; Cohn, Danny M.; Costa, Celia; Craig, Timothy; Criado, Paulo Ricardo; Criado, Roberta F.; Csuka, Dorottya; Dissemond, Joachim; Du-Thanh, Aurelie; Ensina, Luis Felipe; Ertaş, Ragıp; Fabiani, Jose E.; Fantini, Claudio; Farkas, Henriette; Ferrucci, Silvia Mariel; Figueras-Nart, Ignasi; Fili, Natalia L.; Fomina, Daria; Fukunaga, Atsushi; Gelincik, Aslı; Gimenez-Arnau, Ana; Godse, Kiran; Gompels, Mark; Goncalo, Margarida; Gotua, Maia; Gower, Richard; Godse, Kiran; Gompels, Mark; Goncalo, Margarida; Gotua, Maia; Gower, Richard; Grumach, Anete S; Guidos-Fogelbach, Guillermo; Hide, Michihiro; Ilina, Natalia; Inomata, Naoko; Jakob, Thilo; Josviack, Dario O.; Kang, Hye-Ryun; Kaplan, Allen; Kasperska-Zajac, Alicja; Katelaris, Constance; Kessel, Aharon; Kleinheinz, Andreas; Kosnik, Mitja; Krasowska, Dorota; Kulthanan, Kanokvalai; Kumaran, M. Sendhil; Larco Sousa, Jose Ignacio; Longhurst, Hilary J.; Lumry, William; MacGinnitie, Andrew; Magerl, Markus; Makris, Michael P.; Malbran, Alejandro; Marsland, Alexander; Martinez-Saguer, Inmaculada; Medina, Iris V.; Meshkova, Raisa; Metz, Martin; Nasr, Iman; Nicolay, Jan; Nishigori, Chikako V.; Meshkova, Raisa; Metz, Martin; Nasr, Iman; Nicolay, Jan; Nishigori, Chikako; Ohsawa, Isao; Özyurt, Kemal; Papadopoulos, Nikolaos G.; Parisi, Claudio A. S.; Peter, Jonathan Grant; Pfuetzner, Wolfgang; Popov, Todor; Prior, Nieves; Ramon, German D.; Reich, Adam; Reshef, Avner; Rie, and School of Medicine

Abstract

GA(2)LEN UCARE Network

Published
2020

23. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Author

Zuberbier, Torsten, Abdul Latiff, Amir Hamzah, Abuzakouk, Mohamed, Aquilina, Susan, Asero, Riccardo, Baker, Diane, Ballmer-Weber, Barbara, Bangert, Christine, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Brockow, Knut, Brzoza, Zenon, Chong Neto, Herberto Jose, Church, Martin K., Criado, Paulo R., Danilycheva, Inna V., Dressler, Corinna, Ensina, Luis Felipe, Fonacier, Luz, Gaskins, Matthew, Gáspár, Krisztian, Gelincik, Aslı, Giménez-Arnau, Ana, Godse, Kiran, Gonçalo, Margarida, Grattan, Clive, Grosber, Martine, Hamelmann, Eckard, Hébert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Kessel, Aharon, Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas-Linnemann, Désirée, Lauerma, Antti, Leslie, Tabi A., Magerl, Markus, Makris, Michael, Meshkova, Raisa Y., Metz, Martin, Micallef, Daniel, Mortz, Charlotte G., Nast, Alexander, Oude-Elberink, Hanneke, Pawankar, Ruby, Pigatto, Paolo D., Ratti Sisa, Hector, Rojo Gutiérrez, María Isabel, Saini, Sarbjit S., Schmid-Grendelmeier, Peter, Sekerel, Bulent E., Siebenhaar, Frank, Siiskonen, Hanna, Soria, Angele, Staubach-Renz, Petra, Stingeni, Luca, Sussman, Gordon, Szegedi, Andrea, Thomsen, Simon Francis, Vadasz, Zahava, Vestergaard, Christian, Wedi, Bettina, Zhao, Zuotao, Maurer, Marcus, Zuberbier, Torsten, Abdul Latiff, Amir Hamzah, Abuzakouk, Mohamed, Aquilina, Susan, Asero, Riccardo, Baker, Diane, Ballmer-Weber, Barbara, Bangert, Christine, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Brockow, Knut, Brzoza, Zenon, Chong Neto, Herberto Jose, Church, Martin K., Criado, Paulo R., Danilycheva, Inna V., Dressler, Corinna, Ensina, Luis Felipe, Fonacier, Luz, Gaskins, Matthew, Gáspár, Krisztian, Gelincik, Aslı, Giménez-Arnau, Ana, Godse, Kiran, Gonçalo, Margarida, Grattan, Clive, Grosber, Martine, Hamelmann, Eckard, Hébert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Kessel, Aharon, Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas-Linnemann, Désirée, Lauerma, Antti, Leslie, Tabi A., Magerl, Markus, Makris, Michael, Meshkova, Raisa Y., Metz, Martin, Micallef, Daniel, Mortz, Charlotte G., Nast, Alexander, Oude-Elberink, Hanneke, Pawankar, Ruby, Pigatto, Paolo D., Ratti Sisa, Hector, Rojo Gutiérrez, María Isabel, Saini, Sarbjit S., Schmid-Grendelmeier, Peter, Sekerel, Bulent E., Siebenhaar, Frank, Siiskonen, Hanna, Soria, Angele, Staubach-Renz, Petra, Stingeni, Luca, Sussman, Gordon, Szegedi, Andrea, Thomsen, Simon Francis, Vadasz, Zahava, Vestergaard, Christian, Wedi, Bettina, Zhao, Zuotao, and Maurer, Marcus

Abstract

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

Published
2022

24. S2k guideline: Diagnosis and treatment of chronic pruritus

Author

Ständer, Sonja, Zeidler, Claudia, Augustin, Matthias, Darsow, Ulf, Kremer, Andreas E, Legat, Franz J, Koschmieder, Steffen, Kupfer, Jörg, Mettang, Thomas, Metz, Martin, Nast, Alexander, Raap, Ulrike, Schneider, Gudrun, Ständer, Hartmut, Streit, Markus, Schut, Christina, Weisshaar, Elke, Ständer, Sonja, Zeidler, Claudia, Augustin, Matthias, Darsow, Ulf, Kremer, Andreas E, Legat, Franz J, Koschmieder, Steffen, Kupfer, Jörg, Mettang, Thomas, Metz, Martin, Nast, Alexander, Raap, Ulrike, Schneider, Gudrun, Ständer, Hartmut, Streit, Markus, Schut, Christina, and Weisshaar, Elke

Abstract

Pruritus is a cross-disciplinary leading symptom of numerous diseases and represents an interdisciplinary diagnostic and therapeutic challenge. In contrast to acute pruritus, chronic pruritus (CP) is a symptom of various diseases that is usually difficult to treat. Scratching and the development of scratch-associated skin lesions can alter the original skin status. In the presence of an itch-scratch-cycle, even secondary diseases such as chronic prurigo can develop. Chronic pruritus leads to considerable subjective suffering of those affected, which can result in restrictions on the health-related quality of life such as sleep disturbances, anxiety, depressiveness, experience of stigmatization and/or social withdrawal up to clinically relevant psychic comorbidities. Medical care of patients should therefore include (a) interdisciplinary diagnosis and therapy of the triggering underlying disease, (b) therapy of the secondary symptoms of pruritus (dermatological therapy, sleep promotion, in the case of an accompanying or underlying psychological or psychosomatic disease an appropriate psychological-psychotherapeutic treatment) and (c) symptomatic antipruritic therapy. The aim of this interdisciplinary guideline is to define and standardize the therapeutic procedure as well as the interdisciplinary diagnosis of CP. This is the short version of the updated S2k-guideline for chronic pruritus. The long version can be found at www.awmf.org.

Published
2022

27. A comprehensive, tri-national, cross-sectional analysis of characteristics and impact of pruritus in psoriasis

Author

Hawro, M., Sahin, E., Steć, M., Różewicka-Czabańska, M., Raducha, E., Garanyan, L., Philipp, S., Kokolakis, G., Christou, D., Kolkhir, Pavel, Pogorelov, D., Weller, K., Metz, Martin, Sabat, R., Maleszka, R., Olisova, O., Maurer, Marcus, Hawro, T., and Publica

Abstract

Background: Pruritus is prevalent in psoriasis but still many features of pruritus, its response to therapy and its burden in psoriasis remain to be better characterized. Objective: To investigate characteristics and burden of pruritus in an international cohort of patients with psoriasis. Methods: This cross-sectional study included a total of 634 patients and 246 controls from Germany, Poland and Russia. Physicians examined and interviewed participants, recording clinical characteristics, such as severity, therapy and localization of psoriatic lesions. Participants filled out self-reported questionnaires including questions on pruritus severity and impact, characteristics, and response to therapy, and quality of life (QoL). Localization patterns of pruritus and skin lesions were visualized using body heat maps. Results: Most patients (82%) experienced pruritus throughout their disease, and 75% had current pruritus. The majority of patients (64%) perceived pure pruritus, and those who reported additional painful and/or burning sensations (36%) reported overall stronger pruritus. The scalp was the most frequently reported localization of pruritus, even in the absence of skin lesions. Body surface area (BSA) of pruritus was not linked to pruritus intensity, but to BSA of psoriatic lesions (rho = 0.278; P < 0.001). One third of patients (31%) reported impaired sex-life, and 4% had suicidal ideations due to pruritus. In up to one third of patients, psoriasis therapies had little or no effect on pruritus. The only therapeutic option offered to some of these patients were antihistamines, which appeared to be effective in most cases. Conclusion: Pruritus is highly prevalent in psoriasis and is linked to a significant burden. Current psoriasis therapies are frequently insufficient to control pruritus. Managing psoriasis should include the assessment and control of itch. Efficient antipruritic therapies should be developed and be made available for patients with psoriasis.

Published
2022

28. Urticaria

Author

Kolkhir, Pavel, Gimenéz-Arnau, Ana María, Kulthanan, Kanokvalai, Peter, Jonny, Metz, Martin, Maurer, Marcus, and Publica

Abstract

Urticaria is an inflammatory skin disorder that affects up to 20% of the world population at some point during their life. It presents with wheals, angioedema or both due to activation and degranulation of skin mast cells and the release of histamine and other mediators. Most cases of urticaria are acute urticaria, which lasts ≤6 weeks and can be associated with infections or intake of drugs or foods. Chronic urticaria (CU) is either spontaneous or inducible, lasts >6 weeks and persists for >1 year in most patients. CU greatly affects patient quality of life, and is linked to psychiatric comorbidities and high healthcare costs. In contrast to chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) has definite and subtype-specific triggers that induce signs and symptoms. The pathogenesis of CSU consists of several interlinked events involving autoantibodies, complement and coagulation. The diagnosis of urticaria is clinical, but several tests can be performed to exclude differential diagnoses and identify underlying causes in CSU or triggers in CIndU. Current urticaria treatment aims at complete response, with a stepwise approach using second-generation H1 antihistamines, omalizumab and cyclosporine. Novel treatment approaches centre on targeting mediators, signalling pathways and receptors of mast cells and other immune cells. Further research should focus on defining disease endotypes and their biomarkers, identifying new treatment targets and developing improved therapies.

Published
2022

30. Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double‐blind placebo‐controlled study

Author

Dickson, Marion C., primary, Walker, Alexandra, additional, Grattan, Clive, additional, Perry, Hayley, additional, Williams, Nicola, additional, Ratia, Nirav, additional, Dewit, Odile, additional, Gisbert, Sophie, additional, Metz, Martin, additional, and Maurer, Marcus, additional

Published
2021
Full Text
View/download PDF

31. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria

Author

Kolkhir, Pavel, Altrichter, Sabine, Asero, Riccardo, Daschner, Alvaro, Ferrer, Marta, Giménez Arnau, Ana M, Hawro, Tomasz, Jakob, Thilo, Kinaciyan, Tamar, Kromminga, Arno, Konstantinou, George N., Makris, Michael, Metz, Martin, Skov, Per Stahl, Staubach, Petra, Sussman, Gordon, Zhang, Ke, and Maurer, Marcus

Subjects
vitiligo, Immunoassay, Autoimmune thyroiditis, autoantibodies, Autoimmune diseases, autoimmunity, Vitiligo, Autoimmunity, autoimmune thyroiditis, Omalizumab, Chronic urticaria, omalizumab, Original Article, autoimmune diseases, Immunoassay l, immunoassay, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, Autoantibodies
Abstract

Purpose: Patients with chronic spontaneous urticaria (CSU) have an increased risk for comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we evaluated clinical and laboratory features of CSU associated with a higher risk of comorbid autoimmune diseases. Methods: We analyzed records of CSU patients (n = 1,199) for a history or presence of autoimmune diseases. Patients were diagnosed with type IIb autoimmune CSU (aiCSU) if all 3 tests were positive: autologous serum skin test (ASST), basophil histamine release assay (BHRA) and/or basophil activation test (BAT), and IgG autoantibodies against Fc epsilon RI alpha/IgE detected by immunoassay. Results: Twenty-eight percent of CSU patients had at least 1 autoimmune disease. The most prevalent autoimmune diseases were Hashimoto's thyroiditis (HT) (>= 21%) and vitiligo (2%). Two percent of CSU patients had >= 2 autoimmune diseases, most frequently HT plus vitiligo. Comorbid autoimmune diseases, in patients with CSU, were associated with female sex, a family history of autoimmune diseases, and higher rates of hypothyroidism and hyperthyroidism (P < 0.001). Presence of autoimmune diseases was linked to aiCSU (P = 0.02). The risks of having autoimmune diseases were 1.7, 2.9 and 3.3 times higher for CSU patients with a positive ASST, BHRA and BAT, respectively. In CSU patients, markers for autoimmune diseases, antinuclear antibodies and/or IgG anti-thyroid antibodies were associated with non-response to omalizumab treatment (P = 0.013). Conclusions: In CSU, autoimmune diseases are common and linked to type IIb autoimmune CSU. Our results suggest that physicians assess and monitor all adult patients with CSU for signs and symptoms of common autoimmune diseases, especially HT and vitiligo.

Published
2021

32. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria

Author

Kolkhir, Pavel Altrichter, Sabine Asero, Riccardo Daschner, Alvaro Ferrer, Marta Gimenez-Arnau, Ana Hawro, Tomasz and Jakob, Thilo Kinaciyan, Tamar Kromminga, Arno Konstantinou, George N. Makris, Michael Metz, Martin Skov, Per Stahl and Staubach, Petra Sussman, Gordon Zhang, Ke Maurer, Marcus

Abstract

Purpose: Patients with chronic spontaneous urticaria (CSU) have an increased risk for comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we evaluated clinical and laboratory features of CSU associated with a higher risk of comorbid autoimmune diseases. Methods: We analyzed records of CSU patients (n = 1,199) for a history or presence of autoimmune diseases. Patients were diagnosed with type IIb autoimmune CSU (aiCSU) if all 3 tests were positive: autologous serum skin test (ASST), basophil histamine release assay (BHRA) and/or basophil activation test (BAT), and IgG autoantibodies against Fc epsilon RI alpha/IgE detected by immunoassay. Results: Twenty-eight percent of CSU patients had at least 1 autoimmune disease. The most prevalent autoimmune diseases were Hashimoto’s thyroiditis (HT) (>= 21%) and vitiligo (2%). Two percent of CSU patients had >= 2 autoimmune diseases, most frequently HT plus vitiligo. Comorbid autoimmune diseases, in patients with CSU, were associated with female sex, a family history of autoimmune diseases, and higher rates of hypothyroidism and hyperthyroidism (P < 0.001). Presence of autoimmune diseases was linked to aiCSU (P = 0.02). The risks of having autoimmune diseases were 1.7, 2.9 and 3.3 times higher for CSU patients with a positive ASST, BHRA and BAT, respectively. In CSU patients, markers for autoimmune diseases, antinuclear antibodies and/or IgG anti-thyroid antibodies were associated with non-response to omalizumab treatment (P = 0.013). Conclusions: In CSU, autoimmune diseases are common and linked to type IIb autoimmune CSU. Our results suggest that physicians assess and monitor all adult patients with CSU for signs and symptoms of common autoimmune diseases, especially HT and vitiligo.

Published
2021

33. Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity

Author

Sauer, Merle, Scheffel, Jörg, Frischbutter, Stefan, Kolkhir, Pavel, Xiang, Yi-Kui, Siebenhaar, Frank, Altrichter, Sabine, Maurer, Marcus, Metz, Martin, and Krause, Karoline

Subjects
Adult, Male, chronic spontaneous urticaria, Immunology, Autoimmunity, autoimmune disease, Middle Aged, immunoglobulin A, immunoglobulin E, Immunoglobulin M, Humans, Chronic Urticaria, Female, Disease Susceptibility, eosinophils, basophils, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, Original Research, autoreactivity
Abstract

Background: The pathogenesis of chronic spontaneous urticaria (CSU) is still insufficiently understood. Recent findings suggest that immunoglobulins, in particular IgE but also IgA, play a role in the development of CSU. Objective: Our aim was to assess differences in clinical and laboratory markers between CSU patients with and without lower levels of serum IgA and IgE. Methods: We analyzed the data of 606 patients with CSU by dividing them into four groups based on their IgA and IgE levels. The groups were compared for their spectrum of symptoms, disease activity, concomitant autoimmunity and routine laboratory markers. Autoreactivity was assessed by basophil activation test (BAT). Moreover, IgE-anti-thyroid peroxidase (TPO) was measured. Results: Of the patients with lower IgE levels, 66.5% also had lower IgA levels (r=0.316, p

Published
2021
Full Text
View/download PDF

34. In chronic spontaneous urticaria, comorbid depression linked to higher disease activity, and substance P levels

Author

Memet, Bachar; Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Vurgun, Eren; Barlas, Fatma; Metz, Martin; Maurer, Marcus, Memet, Bachar; Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), and Vurgun, Eren; Barlas, Fatma; Metz, Martin; Maurer, Marcus

Abstract

Background: patients with chronic spontaneous urticaria often exhibit psychiatric comorbidities including depression that contribute to the impairment of their quality of life. How CSU and depression are linked isn't well-understood. Substance P has been shown to be increased in patients with CSU and is held to contribute to the pathogenesis of depression. Methods: we measured disease activity in 30 CSU patients without depression and 30 CSU patients with depression by using the urticaria activity score. The severity of depression was assessed with the Beck Depression Inventory. We measured SP levels in these patients as well as in 30 healthy control subjects. In patients with comorbid depression, we correlated SP levels with CSU disease activity and the severity of depression. Results: in CSU patients, disease activity and the severity of depression were positively linked. UAS7 values were higher in CSU patients with comorbid depression as compared to those without (p < 0.05). SP levels were higher in CSU patients with depression than in those without (p < 0.001), but was similar in all CSU patients compared to healthy controls. SP levels weren't correlated with UAS7 values in CSU patients with depression, whereas they were weakly but significantly correlated with BDI scores (p < 0.05). Conclusion: our results suggest that, in CSU patients with comorbid depression, CSU disease activity affects the severity of depression. CSU patients with high disease activity should be explored for comorbid depression.

Published
2021

35. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Author

Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Zuberbier, Torsten; Abdul Latiff, Amir Hamzah; Abuzakouk, Mohamed; Aquilina, Susan; Asero, Riccardo; Baker, Diane; Ballmer-Weber, Barbara; Bangert, Christine; Ben-Shoshan, Moshe; Bernstein, Jonathan A.; Bindslev-Jensen, Carsten; Brockow, Knut; Brzoza, Zenon; Chong Neto, Herberto Jose; Church, Martin K.; Criado, Paulo R.; Danilycheva, Inna V.; Dressler, Corinna; Ensina, Luis Felipe; Fonacier, Luz; Gaskins, Matthew; Gaspar, Krisztian; Gelincik, Asli; Gimenez-Arnau, Ana; Godse, Kiran; Goncalo, Margarida; Grattan, Clive; Grosber, Martine; Hamelmann, Eckard; Hebert, Jacques; Hide, Michihiro; Kaplan, Allen; Kapp, Alexander; Kessel, Aharon; Kulthanan, Kanokvalai; Larenas-Linnemann, Desiree; Lauerma, Antti; Leslie, Tabi A.; Magerl, Markus; Makris, Michael; Meshkova, Raisa Y.; Metz, Martin; Micallef, Daniel; Mortz, Charlotte G.; Nast, Alexander; Oude-Elberink, Hanneke; Pawankar, Ruby; Pigatto, Paolo D.; Ratti Sisa, Hector; Rojo Gutierrez, Maria Isabel; Saini, Sarbjit S.; Schmid-Grendelmeier, Peter; Sekerel, Bulent E.; Siebenhaar, Frank; Siiskonen, Hanna; Soria, Angele; Staubach-Renz, Petra; Stingeni, Luca; Sussman, Gordon; Szegedi, Andrea; Thomsen, Simon Francis; Vadasz, Zahava; Vestergaard, Christian; Wedi, Bettina; Zhao, Zuotao; Maurer, Marcus, School of Medicine, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Zuberbier, Torsten; Abdul Latiff, Amir Hamzah; Abuzakouk, Mohamed; Aquilina, Susan; Asero, Riccardo; Baker, Diane; Ballmer-Weber, Barbara; Bangert, Christine; Ben-Shoshan, Moshe; Bernstein, Jonathan A.; Bindslev-Jensen, Carsten; Brockow, Knut; Brzoza, Zenon; Chong Neto, Herberto Jose; Church, Martin K.; Criado, Paulo R.; Danilycheva, Inna V.; Dressler, Corinna; Ensina, Luis Felipe; Fonacier, Luz; Gaskins, Matthew; Gaspar, Krisztian; Gelincik, Asli; Gimenez-Arnau, Ana; Godse, Kiran; Goncalo, Margarida; Grattan, Clive; Grosber, Martine; Hamelmann, Eckard; Hebert, Jacques; Hide, Michihiro; Kaplan, Allen; Kapp, Alexander; Kessel, Aharon; Kulthanan, Kanokvalai; Larenas-Linnemann, Desiree; Lauerma, Antti; Leslie, Tabi A.; Magerl, Markus; Makris, Michael; Meshkova, Raisa Y.; Metz, Martin; Micallef, Daniel; Mortz, Charlotte G.; Nast, Alexander; Oude-Elberink, Hanneke; Pawankar, Ruby; Pigatto, Paolo D.; Ratti Sisa, Hector; Rojo Gutierrez, Maria Isabel; Saini, Sarbjit S.; Schmid-Grendelmeier, Peter; Sekerel, Bulent E.; Siebenhaar, Frank; Siiskonen, Hanna; Soria, Angele; Staubach-Renz, Petra; Stingeni, Luca; Sussman, Gordon; Szegedi, Andrea; Thomsen, Simon Francis; Vadasz, Zahava; Vestergaard, Christian; Wedi, Bettina; Zhao, Zuotao; Maurer, Marcus, and School of Medicine

Abstract

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA(2)LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria., Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs); European Union (EU); 6th Framework Programme; Global Allergy and Asthma European Network (GA2LEN); European Academy of Allergology and Clinical Immunology (EAACI); Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI); European Dermatology Forum (EDF)

Published
2021

36. Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice

Author

Akahoshi, Mitsuteru, Ho Song, Chang, Piliponsky, Adrian M., Metz, Martin, Guzzetta, Andrew, Abrink, Magnus, Schlenner, Susan M., Feyerabend, Thorsten B., Rodewald, Hans-Reimer, Pejler, Gunnar, Tsai, Mindy, and Galli, Stephen J.

Subjects
Proteases -- Physiological aspects -- Research, Venom -- Health aspects -- Research, Mast cells -- Physiological aspects -- Research, Health care industry
Abstract

Mast cell degranulation is important in the pathogenesis of anaphylaxis and allergic disorders. Many animal venoms contain components that can induce mast cell degranulation, and this has been thought to contribute to the pathology and mortality caused by envenomation. However, we recently reported evidence that mast cells can enhance the resistance of mice to the venoms of certain snakes and that mouse mast cell-derived carboxypeptidase A3 (CPA3) can contribute to this effect. Here, we investigated whether mast cells can enhance resistance to the venom of the Gila monster, a toxic component of that venom (helodermin), and the structurally similar mammalian peptide, vasoactive intestinal polypeptide (VIP). Using 2 types of mast cell-deficient mice, as well as mice selectively lacking CPA3 activity or the chymase mouse mast cell protease-4 (MCPT4), we found that mast cells and MCPT4, which can degrade helodermin, can enhance host resistance to the toxicity of Gila monster venom. Mast cells and MCPT4 also can limit the toxicity associated with high concentrations of VIP and can reduce the morbidity and mortality induced by venoms from 2 species of scorpions. Our findings support the notion that mast cells can enhance innate defense by degradation of diverse animal toxins and that release of MCPT4, in addition to CPA3, can contribute to this mast cell function., Introduction In addition to their roles as effector cells in anaphylaxis and allergic disorders, there is evidence that mast cells can enhance innate host defense through functions such as directly [...]

Published
2011
Full Text
View/download PDF

37. T cell killing by tolerogenic dendritic cells protects mice from allergy

Author

Luckey, Ulrike, Maurer, Marcus, Schmidt, Talkea, Lorenz, Nadine, Seebach, Beate, Metz, Martin, and Steinbrink, Kerstin

Subjects
T cells -- Physiological aspects -- Research, Allergic reaction -- Development and progression -- Research, Dendritic cells -- Physiological aspects -- Research, Apoptosis -- Research, Allergy -- Development and progression -- Research, Health care industry
Abstract

It is well established that allergy development can be prevented by repeated low-dose exposure to contact allergens. Exactly which immune mechanisms are responsible for this so-called low zone tolerance (LZT) is not clear, although [CD8.sup.+] suppressor T cells are known to have a role. Here, we show that TNF released by tolerogenic [[CD11.sup.+]CD8.sup.+] DCs located in skin-draining lymph nodes is required and sufficient for development of tolerance to contact allergens in mice. DC-derived TNF protected mice from contact allergy by inducing apoptosis in allergen-specific effector [CD8.sup.+] T cells via TNF receptor 2 but did not contribute to the generation and function of the regulatory T cells associated with LZT. The TNF-mediated killing mechanism was induced in an allergen-specific manner. Activation of tolerogenic DCs by LZT [CD8.sup.+] suppressor T cells and enhanced TNF receptor 2 expression on contact allergen-specific [CD8.sup.+] effector T cells were required for LZT. Our findings may explain how tolerance protects from allergic diseases, which could allow for the development of new strategies for allergy prevention., Introduction Although everyone is exposed to a multitude of potent contact allergens, contact allergies affect only about 10% of the population (1). It is widely held that tolerance induction by [...]

Published
2011
Full Text
View/download PDF

40. Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis

Author

Piliponsky, Adrian M., Chen, Ching-Cheng, Nishimura, Toshihiko, Metz, Martin, Rios, Eon J., Dobner, Paul R., Wada, Etsuko, Wada, Keiji, Zacharias, Sherma, Mohanasundaram, Uma M., Faix, James D., Abrink, Magnus, Pejler, Gunnar, Pearl, Ronald G., Tsai, Mindy, and Galli, Stephen J.

Abstract

Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to infection. Neurotensin (NT) is a 13-amino-acid peptide that, among its multiple effects, induces hypotension. We find that intraperitoneal and plasma concentrations of NT are increased in mice after severe cecal ligation and puncture (CLP), a model of sepsis, and that mice treated with a pharmacological antagonist of NT, or NT deficient mice, show reduced mortality during severe CLIP. In mice, mast cells can degrade NT and reduce NT-induced hypotension and CLP-associated mortality, and optimal expression of these effects requires mast cell expression of neurotensin receptor 1 and neurolysin. These findings show that NT contributes to sepsis-related mortality in mice during severe CLIP and that mast cells can lower NT concentrations, and suggest that mast cell-dependent reduction in NT levels contributes to the ability of mast cells to enhance survival after CLP., Sepsis is the most common cause of death in intensive care units in the United States (1). The host response to sepsis is complex, yet the factors responsible for the [...]

Published
2008

41. Definition, aims, and implementation of GA 2 LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Maurer, Marcus, Aberer, Werner, Agondi, Rosana, Al���Ahmad, Mona, Al���Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Ayg��ren���P��rs��n, Emel, Banerji, Aleena, Bauer, Andrea, Ben���Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A., Betschel, Stephen, Bindslev���Jensen, Carsten, Bizjak, Mojca, Boccon���Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby���Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, R��gis A., Cancian, Mauro, Cherrez���Ojeda, Ivan, Cohn, Danny M., Costa, C��lia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du���Thanh, Aur��lie, Ensina, Luis Felipe, Erta��, Rag��p, Fabiani, Jos�� E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras���Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Asli, Gim��nez���Arnau, Ana, Godse, Kiran, Gompels, Mark, Gon��alo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S., Guidos���Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye���Ryun, Kaplan, Allen, Kasperska���Zaj��c, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kocat��rk, Emek, Ko��nik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jos�� Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbr��n, Alejandro, Marsland, Alexander, Martinez���Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako, Ohsawa, Isao, ��zyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pf��tzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, R��ckmann���Helmbach, Heike, Rudenko, Michael, Salman, Anda��, Sanchez���Borges, Mario, Schmid���Grendelmeier, Peter, Serpa, Faradiba S., Serra���Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Ang��le, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, Doorn, Martijn, Varga, Lilian, V��zquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber���Chrysochoou, Christina, Ye, Young���Min, Zalewska���Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., and Castaldo, Anthony

Subjects
urticaria, center, angioedema, excellence, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, management
Published
2020

42. Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Maurer, Marcus, Aberer, Werner, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygören-Pürsü, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A., Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Régis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Célia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurélie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, José E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Asli, Giménez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Gonçalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S., Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zając, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kocatürk, Emek, Košnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, José Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbrán, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfützner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Röckmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angèle, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vázquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., and Castaldo, Anthony

Subjects
Medizin
Published
2020

43. Definition, aims, and implementation of GA(2)LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Maurer, Marcus Werner, Aberer Agondi, Rosana Al-Ahmad, Mona and Al-Nesf, Maryam Ali Ansotegui, Ignacio Arnaout, Rand and Arruda, Luisa Karla Asero, Riccardo Aygoeren-Puersue, Emel and Banerji, Aleena Bauer, Andrea Ben-Shoshan, Moshe Berardi, Alejandro Bernstein, Jonathan A. Betschel, Stephen and Bindslev-Jensen, Carsten Bizjak, Mojca Boccon-Gibod, Isabelle and Bork, Konrad Bouillet, Laurence Boysen, Henrik Balle and Brodszki, Nicholas Broesby-Olsen, Sigurd Busse, Paula and Buttgereit, Thomas Bygum, Anette Caballero, Teresa Campos, Regis A. Cancian, Mauro Cherrez-Ojeda, Ivan Cohn, Danny M. and Costa, Celia Craig, Timothy Criado, Paulo Ricardo and Criado, Roberta F. Csuka, Dorottya Dissemond, Joachim and Du-Thanh, Aurelie Ensina, Luis Felipe Ertas, Ragip Fabiani, Jose E. Fantini, Claudio Farkas, Henriette Ferrucci, Silvia Mariel Figueras-Nart, Ignasi Fili, Natalia L. Fomina, Daria and Fukunaga, Atsushi Gelincik, Asli Gimenez-Arnau, Ana and Godse, Kiran Gompels, Mark Goncalo, Margarida Gotua, Maia and Gower, Richard Grumach, Anete S. Guidos-Fogelbach, Guillermo and Hide, Michihiro Ilina, Natalia Inomata, Naoko Jakob, Thilo Josviack, Dario O. Kang, Hye-Ryun Kaplan, Allen and Kasperska-Zajac, Alicja Katelaris, Constance Kessel, Aharon and Kleinheinz, Andreas Kocaturk, Emek Kosnik, Mitja Krasowska, Dorota Kulthanan, Kanokvalai Kumaran, M. Sendhil Larco Sousa, Jose Ignacio Longhurst, Hilary J. Lumry, William and MacGinnitie, Andrew Magerl, Markus Makris, Michael P. and Malbran, Alejandro Marsland, Alexander Martinez-Saguer, Inmaculada Medina, Iris V. Meshkova, Raisa Metz, Martin and Nasr, Iman Nicolay, Jan Nishigori, Chikako Ohsawa, Isao and Ozyurt, Kemal Papadopoulos, Nikolaos G. Parisi, Claudio A. S. and Peter, Jonathan Grant Pfuetzner, Wolfgang Popov, Todor and Prior, Nieves Ramon, German D. Reich, Adam Reshef, Avner and Riedl, Marc A. Ritchie, Bruce Rockmann-Helmbach, Heike and Rudenko, Michael Salman, Andac Sanchez-Borges, Mario and Schmid-Grendelmeier, Peter Serpa, Faradiba S. Serra-Baldrich, Esther Sheikh, Farrukh R. Smith, William Soria, Angele and Staubach, Petra Steiner, Urs C. Stobiecki, Marcin Sussman, Gordon Tagka, Anna Thomsen, Simon Francis Treudler, Regina and Valle, Solange van Doorn, Martijn Varga, Lilian Vazquez, Daniel O. Wagner, Nicola Wang, Liangchun Weber-Chrysochoou, Christina Ye, Young-Min Zalewska-Janowska, Anna Zanichelli, Andrea Zhao, Zuotao Zhi, Yuxiang Zuberbier, Torsten and Zwiener, Ricardo D. Castaldo, Anthony

Published
2020

44. IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities

Author

Orinska, Zane, Maurer, Marcus, Mirghomizadeh, Farhad, Bulanova, Elena, Metz, Martin, Nashkevich, Natalia, Schiemann, Florian, Schulmistrat, Jan, Budagian, Vadim, Giron-Michel, Julien, Brandt, Ernst, Paus, Ralf, and Bulfone-Paus, Silvia

Abstract

Sepsis remains a global clinical problem. By using the mouse cecal ligation and puncture model of sepsis, here we identify an important aspect of mast cell (MC)-dependent, innate immune defenses against Gram-negative bacteria by demonstrating that MC protease activity is regulated by interleukin-15 (IL-15). Mouse MCs express both constitutive and lipopolysaccharide-inducible IL-15 and store it intracellularly. Deletion of Il15 in mice markedly increases chymase activities, leading to greater MC bactericidal responses, increased processing and activation of neutrophil-recruiting chemokines, and significantly higher survival rates of mice after septic peritonitis. By showing that intracellular IL-15 acts as a specific negative transcriptional regulator of a mouse MC chymase (mast cell protease-2), we provide evidence that defined MC protease activity is transcriptionally regulated by an intracellularly retained cytokine. Our results identify an unexpected breach in MC-dependent innate immune defenses against sepsis and suggest that inhibiting intracellular IL-15 in MCs may improve survival from sepsis., Author(s): Zane Orinska [1, 6]; Marcus Maurer [2, 6]; Farhad Mirghomizadeh [1, 6]; Elena Bulanova [1]; Martin Metz [2, 3]; Natalia Nashkevich [1]; Florian Schiemann [1]; Jan Schulmistrat [1]; Vadim [...]

Published
2007
Full Text
View/download PDF

45. Urticaria : Collegium Internationale Allergologicum (CIA) Update 2020

Author

Maurer, Marcus, Eyerich, Kilian, Eyerich, Stefanie, Ferrer, Marta, Gutermuth, Jan, Hartmann, Karin, Jakob, Thilo, Kapp, Alexander, Kolkhir, Pavel, Larenas-Linnemann, Desiree, Park, Hae-Sim, Pejler, Gunnar, Sanchez-Borges, Mario, Schaekel, Knut, Simon, Dagmar, Simon, Hans-Uwe, Weller, Karsten, Zuberbier, Torsten, Metz, Martin, Maurer, Marcus, Eyerich, Kilian, Eyerich, Stefanie, Ferrer, Marta, Gutermuth, Jan, Hartmann, Karin, Jakob, Thilo, Kapp, Alexander, Kolkhir, Pavel, Larenas-Linnemann, Desiree, Park, Hae-Sim, Pejler, Gunnar, Sanchez-Borges, Mario, Schaekel, Knut, Simon, Dagmar, Simon, Hans-Uwe, Weller, Karsten, Zuberbier, Torsten, and Metz, Martin

Abstract

This update on chronic urticaria (CU) focuses on the prevalence and pathogenesis of chronic spontaneous urticaria (CSU), the expanding spectrum of patient-reported outcome measures (PROMs) for assessing CU disease activity, impact, and control, as well as future treatment options for CU. This update is needed, as several recently reported findings have led to significant advances in these areas. Some of these key discoveries were first presented at past meetings of the Collegium Internationale Allergologicum (CIA). New evidence shows that the prevalence of CSU is geographically heterogeneous, high in all age groups, and increasing. Several recent reports have helped to better characterize two endotypes of CSU: type I autoimmune (or autoallergic) CSU, driven by IgE to autoallergens, and type IIb autoimmune CSU, which is due to mast cell (MC)-targeted autoantibodies. The aim of treatment in CU is complete disease control with absence of signs and symptoms as well as normalization of quality of life (QoL). This is best monitored by the use of an expanding set of PROMs, to which the Angioedema Control Test, the Cholinergic Urticaria Quality of Life Questionnaire, and the Cholinergic Urticaria Activity Score have recently been added. Current treatment approaches for CU under development include drugs that inhibit the effects of signals that drive MC activation and accumulation, drugs that inhibit intracellular pathways of MC activation and degranulation, and drugs that silence MCs by binding to inhibitory receptors. The understanding, knowledge, and management of CU are rapidly increasing. The aim of this review is to provide physicians who treat CU patients with an update on where we stand and where we will go. Many questions and unmet needs remain to be addressed, such as the development of routine diagnostic tests for type I and type IIb autoimmune CSU, the global dissemination and consistent use of PROMs to assess disease activity, impact, and control, and the develo

Published
2020
Full Text
View/download PDF

46. Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction

Author

Pereira, Manuel P, Zeidler, Claudia, Wallengren, Joanna, Halvorsen, Jon A, Weisshaar, Elke, Garcovich, Simone, Misery, Laurent, Brenaut, Emilie, Şavk, Ekin, Potekaev, Nikolay, Lvov, Andrey, Bobko, Svetlana, Szepietowski, Jacek C, Reich, Adam, Bozek, Agnieszka, Legat, Franz J, Metz, Martin, Streit, Marku, Serra-Baldrich, Esther, Gonçalo, Margarida, Storck, Michael, Nau, Teresa, Hoffmann, Vincent, Steinke, Sabine, Greiwe, Ina, Dugas, Martin, Augustin, Matthia, Ständer, Sonja, Garcovich, Simone (ORCID:0000-0001-8967-6688), Pereira, Manuel P, Zeidler, Claudia, Wallengren, Joanna, Halvorsen, Jon A, Weisshaar, Elke, Garcovich, Simone, Misery, Laurent, Brenaut, Emilie, Şavk, Ekin, Potekaev, Nikolay, Lvov, Andrey, Bobko, Svetlana, Szepietowski, Jacek C, Reich, Adam, Bozek, Agnieszka, Legat, Franz J, Metz, Martin, Streit, Marku, Serra-Baldrich, Esther, Gonçalo, Margarida, Storck, Michael, Nau, Teresa, Hoffmann, Vincent, Steinke, Sabine, Greiwe, Ina, Dugas, Martin, Augustin, Matthia, Ständer, Sonja, and Garcovich, Simone (ORCID:0000-0001-8967-6688)

Abstract

Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.

Published
2020

47. Management of urticarial vasculitis: a worldwide physician perspective

Author

Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Kolkhir, Pavel; Bonnekoh, Hanna; Hide, Michihiro; Metz, Martin; Sanchez-Borges, Mario; Krause, Karoline; Maurer, Marcus, School of Medicine, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Kolkhir, Pavel; Bonnekoh, Hanna; Hide, Michihiro; Metz, Martin; Sanchez-Borges, Mario; Krause, Karoline; Maurer, Marcus, and School of Medicine

Abstract

Background: urticarial vasculitis (UV) is a rare type of leukocytoclastic vasculitis characterized by long lasting urticarial skin lesions and poor response to treatment. As of yet, no clinical guidelines, diagnostic criteria, or treatment algorithms exist, and the approaches to the diagnostic workup and treatment of UV patients may differ globally. We conducted an online survey to examine how UV patients are diagnosed and treated by international specialists and to reveal the greatest challenges in managing UV patients worldwide. Methods: distribution of the questionnaire included an email to individuals in the World Allergy Organization (WAO) database, with no restrictions applied to the specialty, affiliation, or nationality of the participants (November 2018). The email contained a link (Internet address) to the online questionnaire. Responses were anonymous. The link to the questionnaire was further sent to the network of Urticaria Centers of Reference and Excellence (UCARE) in the Global Allergy and Asthma European Network (GA2LEN) as well as to the Turkish Dermatology Society and the Japanese Society of Allergology, who distributed the link to their members. In addition, the survey link was posted online in the group of the Russian Society of Allergologists and Immunologists. Results: we received 883 completed surveys from physicians in 92 countries. UV was reported to be rare in clinical practice, with an average of 5 patients per physician per year. More than two-thirds of physicians reported wheals, burning of the skin, and residual hyperpigmentation in 60–100% of UV patients. The most frequently reported reason for receiving referrals of patients with UV was to establish the diagnosis. The most important features for establishing the diagnosis of UV were wheals of longer than 24 hours duration (72%), the results of skin biopsy (63%), and post-inflammatory hyperpigmentation (46%). The most common tests ordered in UV patients were complete blood count, eryt, NA

Published
2020

49. Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria

Author

Kolkhir, Pavel, primary, Altrichter, Sabine, additional, Asero, Riccardo, additional, Daschner, Alvaro, additional, Ferrer, Marta, additional, Giménez-Arnau, Ana, additional, Hawro, Tomasz, additional, Jakob, Thilo, additional, Kinaciyan, Tamar, additional, Kromminga, Arno, additional, Konstantinou, George N, additional, Makris, Michael, additional, Metz, Martin, additional, Skov, Per Stahl, additional, Staubach, Petra, additional, Sussman, Gordon, additional, Zhang, Ke, additional, and Maurer, Marcus, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results